# Neothetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neothetics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.neothetics.com
- Total disclosed funding: $37M
- Latest round: Series C (Feb 12, 2014)
- Investors on record: 7

## About

Neothetics, Inc. specializes in the domain sales industry, providing a platform for premium domain names, enhancing digital presence for businesses and individuals through unique web addresses.Founded in 2007 and headquartered in San Diego, US, Neothetics, Inc. operates within the domain sales space. The company completed its latest funding round, an IPO, in November 2014, raising USD 65 mn and selling shares on the Nasdaq. In January 2018, Neothetics agreed to merge with Evofem Biosciences, Inc., continuing operations under the Evofem name. The founder's background is not specified, and the company has completed 7 deals to date.Neothetics.com primarily operates as a domain sales platform offering premium domain names for immediate purchase or structured payment plans. Each domain aids businesses and individuals in enhancing their digital identity and brand visibility. Catering to startups and established enterprises globally, the platform focuses on regions such as North America, Europe, and Australia, addressing the demand for memorable web addresses while ensuring seamless domain transactions.In the most recent fiscal year of 2014, Neothetics reported no revenue. The EBITDA for the same year was USD -11,973,206. The revenue model centers on direct sales of domain names, allowing clients to purchase outright or through installment plans with prices varying in the thousands of USD, reflecting market demand. The company also provides additional services like WhoIs Privacy Protection, facilitating straightforward B2C transactions with a 30-day satisfaction guarantee.Neothetics, Inc. plans to enhance its product offerings and expand its market reach. The recent IPO funding of USD 65 mn will be utilized to develop new domain-related services and enhance its platform capabilities. Following its merger with Evofem Biosciences, the company will focus on integrating their offerings by 2018 and expanding further into English-speaking markets, improving their service delivery and customer engagement.

## Funding rounds

- Series C, Feb 12, 2014, $8M — Alta Partners, Domain Associates, AKS Capital
- Series C, Jul 18, 2013, $6.7M — RMI Partners, Mirae Asset Venture Investment
- Series C, Dec 17, 2012, $21M — Alta Partners, Domain Associates, Numoda Capital Innovations, Amorepacific Ventures, RMI Partners
- Series A, Mar 7, 2007, $1.5M — Alta Partners, Domain Associates

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series C
- Numoda Capital Innovations — Series C
- Amorepacific Ventures (https://capitalatlas.ai/funds/amorepacific-ventures) — Series C
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series C
- AKS Capital (https://capitalatlas.ai/funds/aks-capital) — Series C